Collin C John1, Michael D Regier2, Christa L Lilly2, Shahenda Aly3. 1. Department of Pediatrics, West Virginia University School of Medicine, Morgantown, WV, USA. Electronic address: cjohn@hsc.wvu.edu. 2. Department of Biostatistics, West Virginia University School of Public Health, Morgantown, WV, USA. 3. Department of Pediatrics, West Virginia University School of Medicine, Morgantown, WV, USA.
Abstract
BACKGROUND: There is limited research detailing low-density lipoprotein cholesterol (LDL-C) trends over the long term in children on various lipid-lowering medications. OBJECTIVES: This study sought to assess factors associated with stability of LDL-C levels in children on long-term pharmacotherapy and their ability to reach the LDL-C goal of ≤130 mg/dL while on pharmacotherapy. METHODS: Medical records of children seen in a university pediatric cholesterol clinic between 1998 and 2012 treated with a statin, ezetimibe, or both were reviewed. Aggregate data were obtained to determine the number of children able to reach an LDL-C level of ≤130 mg/dL while on pharmacotherapy. Kaplan-Meier curve and proportional hazard regression analysis were used to examine the propensity for LDL-C levels to stabilize over time while on pharmacotherapy as well as factors affecting this propensity. RESULTS: Overall, 76 patients who contributed 864 total visits were included. Of the 76 patients, 56 developed a stable LDL-C with median time to stability of 28 months on pharmacotherapy. Younger age at first visit and higher medication potencies/doses were associated with an increased propensity to stabilize. Only 36 patients were able to reach an LDL-C of ≤130 mg/dL, with only 11 of 38 patients with probable familial hypercholesterolemia reaching this goal. CONCLUSIONS: Most children reached LDL-C stability on pharmacotherapy after a median 28-month interval. However, most children had difficulty in reaching the LDL-C goal of ≤130 mg/dL even with aggressive medication titration. This was specifically true for those with probable familial hypercholesterolemia.
BACKGROUND: There is limited research detailing low-density lipoprotein cholesterol (LDL-C) trends over the long term in children on various lipid-lowering medications. OBJECTIVES: This study sought to assess factors associated with stability of LDL-C levels in children on long-term pharmacotherapy and their ability to reach the LDL-C goal of ≤130 mg/dL while on pharmacotherapy. METHODS: Medical records of children seen in a university pediatric cholesterol clinic between 1998 and 2012 treated with a statin, ezetimibe, or both were reviewed. Aggregate data were obtained to determine the number of children able to reach an LDL-C level of ≤130 mg/dL while on pharmacotherapy. Kaplan-Meier curve and proportional hazard regression analysis were used to examine the propensity for LDL-C levels to stabilize over time while on pharmacotherapy as well as factors affecting this propensity. RESULTS: Overall, 76 patients who contributed 864 total visits were included. Of the 76 patients, 56 developed a stable LDL-C with median time to stability of 28 months on pharmacotherapy. Younger age at first visit and higher medication potencies/doses were associated with an increased propensity to stabilize. Only 36 patients were able to reach an LDL-C of ≤130 mg/dL, with only 11 of 38 patients with probable familial hypercholesterolemia reaching this goal. CONCLUSIONS: Most children reached LDL-C stability on pharmacotherapy after a median 28-month interval. However, most children had difficulty in reaching the LDL-C goal of ≤130 mg/dL even with aggressive medication titration. This was specifically true for those with probable familial hypercholesterolemia.
Authors: Jessica Rodenburg; Maud N Vissers; Albert Wiegman; A S Paul van Trotsenburg; Anouk van der Graaf; Eric de Groot; Frits A Wijburg; John J P Kastelein; Barbara A Hutten Journal: Circulation Date: 2007-07-30 Impact factor: 29.690
Authors: Neil J Stone; Jennifer G Robinson; Alice H Lichtenstein; C Noel Bairey Merz; Conrad B Blum; Robert H Eckel; Anne C Goldberg; David Gordon; Daniel Levy; Donald M Lloyd-Jones; Patrick McBride; J Sanford Schwartz; Susan T Shero; Sidney C Smith; Karol Watson; Peter W F Wilson Journal: J Am Coll Cardiol Date: 2013-11-12 Impact factor: 24.094
Authors: H C Knipscheer; C C Boelen; J J Kastelein; D E van Diermen; B E Groenemeijer; A van den Ende; H R Büller; H D Bakker Journal: Pediatr Res Date: 1996-05 Impact factor: 3.756
Authors: Anouk van der Graaf; Melchior C Nierman; Jean C Firth; Karen H Wolmarans; A David Marais; Eric de Groot Journal: Acta Paediatr Date: 2006-11 Impact factor: 2.299
Authors: Robert J Kuczmarski; Cynthia L Ogden; Shumei S Guo; Laurence M Grummer-Strawn; Katherine M Flegal; Zuguo Mei; Rong Wei; Lester R Curtin; Alex F Roche; Clifford L Johnson Journal: Vital Health Stat 11 Date: 2002-05
Authors: Albert Wiegman; Barbara A Hutten; Eric de Groot; Jessica Rodenburg; Henk D Bakker; Harry R Büller; Eric J G Sijbrands; John J P Kastelein Journal: JAMA Date: 2004-07-21 Impact factor: 56.272
Authors: Saskia de Jongh; Leiv Ose; Tamás Szamosi; Claude Gagné; M Lambert; Russell Scott; P Perron; Dries Dobbelaere; M Saborio; Mary B Tuohy; Michael Stepanavage; Aditi Sapre; Barry Gumbiner; Michele Mercuri; A S Paul van Trotsenburg; Henk D Bakker; John J P Kastelein Journal: Circulation Date: 2002-10-22 Impact factor: 29.690
Authors: Ivana Semova; Amy E Levenson; Joanna Krawczyk; Kevin Bullock; Kathryn A Williams; R Paul Wadwa; Amy S Shah; Philip R Khoury; Thomas R Kimball; Elaine M Urbina; Sarah D de Ferranti; Franziska K Bishop; David M Maahs; Lawrence M Dolan; Clary B Clish; Sudha B Biddinger Journal: J Clin Lipidol Date: 2019-09-25 Impact factor: 4.766
Authors: Nina R Joyce; Gregory A Wellenius; Charles B Eaton; Amal N Trivedi; Justin P Zachariah Journal: J Clin Lipidol Date: 2016-03-10 Impact factor: 4.766